Castration-resistant* prostate carcinoma with at least 1 of the following: | n (%) |
C1. Histologic evidence of small cell prostate carcinoma (pure or mixed). | 29 (25.4) |
C2. Exclusively visceral metastases. | 19 (16.7) |
C3. Radiographically predominant lytic bone metastases by plain radiograph or CT scan. | 16 (14.0) |
C4. Bulky (≥5 cm) lymphadenopathy OR bulky (≥5 cm) high-grade (Gleason ≥8) tumor mass in the prostate/pelvis. | 49 (43.0) |
C5. Low PSA (≤10 ng/mL) at initial presentation (prior to ADT or at symptomatic progression in the castrate setting) PLUS high-volume (≥20) bone metastases. | 26 (22.8) |
C6. Presence of neuroendocrine markers on histology (positive staining of chromogranin A or synaptophysin) OR in serum (abnormal high serum levels for chromogranin A or GRP) at initial diagnosis or at progression. PLUS any of the following in the absence of other causes:
| 21 (18.4) |
C7. Short interval (≤6 months) to androgen-independent progression following the initiation of hormonal therapy, with or without the presence of neuroendocrine markers. | 52 (45.6) |
Do you want to add Medilib to your home screen?